BACKGROUND: The purpose of this study was to compare long-term effects of cariporide with those of losartan in postinfarction heart failure. METHODS AND RESULTS:Female Sprague-Dawley rats with large myocardial infarctions and sham controls were randomized to losartan, cariporide, or placebo after 7 days and treated for 49 days. Cardiac function was assessed by echocardiography and measurement of left ventricular pressures, and gene expression was assessed by competitive reverse transcription-polymerase chain reaction. Cell dimensions, shortening, and relaxation were determined by videomicroscopy and calcium transients by fura 2. Losartan reduced postinfarction systolic and diastolic left ventricular dilation (by 24% and 31%, respectively), left and right ventricular weight (by 22% and 26%, respectively), and cardiomyocyte hypertrophy length and width (by 62% and 54%, respectively). Induction of myocardial atrial natriuretic peptide decreased 66%. Cariporide did not affect postinfarction hypertrophy or atrial natriuretic peptide. Losartan and cariporide respectively improved reduced cellular contractility (55% and 30%) and reduced elevated systolic (86% and 27%) and diastolic (49% and 43%) calcium. Losartan and cariporide respectively reduced prolonged time to 50% relaxation (66% and 25%) and time to 50% calcium reduction (55% and 53%). CONCLUSIONS:Losartan and cariporide improve cardiomyocyte contractility and calcium regulation in chronic heart failure. Losartan has salutary effects on postinfarction remodeling and gene expression, whereas cariporide is neutral.
RCT Entities:
BACKGROUND: The purpose of this study was to compare long-term effects of cariporide with those of losartan in postinfarction heart failure. METHODS AND RESULTS: Female Sprague-Dawley rats with large myocardial infarctions and sham controls were randomized to losartan, cariporide, or placebo after 7 days and treated for 49 days. Cardiac function was assessed by echocardiography and measurement of left ventricular pressures, and gene expression was assessed by competitive reverse transcription-polymerase chain reaction. Cell dimensions, shortening, and relaxation were determined by videomicroscopy and calcium transients by fura 2. Losartan reduced postinfarction systolic and diastolic left ventricular dilation (by 24% and 31%, respectively), left and right ventricular weight (by 22% and 26%, respectively), and cardiomyocyte hypertrophy length and width (by 62% and 54%, respectively). Induction of myocardial atrial natriuretic peptide decreased 66%. Cariporide did not affect postinfarction hypertrophy or atrial natriuretic peptide. Losartan and cariporide respectively improved reduced cellular contractility (55% and 30%) and reduced elevated systolic (86% and 27%) and diastolic (49% and 43%) calcium. Losartan and cariporide respectively reduced prolonged time to 50% relaxation (66% and 25%) and time to 50% calcium reduction (55% and 53%). CONCLUSIONS:Losartan and cariporide improve cardiomyocyte contractility and calcium regulation in chronic heart failure. Losartan has salutary effects on postinfarction remodeling and gene expression, whereas cariporide is neutral.
Authors: Steve Lancel; Fuzhong Qin; Shannon L Lennon; Jingmei Zhang; Xiaoyong Tong; Michael J Mazzini; Y James Kang; Deborah A Siwik; Richard A Cohen; Wilson S Colucci Journal: Circ Res Date: 2010-05-27 Impact factor: 17.367
Authors: Hartmut Ruetten; Doris Gehring; Katrin Hiss; Ursula Schindler; Martin Gerl; Andreas E Busch; Stefan Schaefer Journal: Br J Pharmacol Date: 2005-11 Impact factor: 8.739
Authors: Ole J Kemi; Morten A Hoydal; Niall Macquaide; Per M Haram; Lauren G Koch; Steven L Britton; Oyvind Ellingsen; Godfrey L Smith; Ulrik Wisloff Journal: J Cell Physiol Date: 2011-09 Impact factor: 6.384
Authors: Katrin Rungwerth; Ursula Schindler; Martin Gerl; Stefan Schäfer; Thomas Licher; Andreas E Busch; Hartmut Ruetten Journal: Br J Pharmacol Date: 2004-07-05 Impact factor: 8.739
Authors: Markus B Sikkel; Darrel P Francis; James Howard; Fabiana Gordon; Christina Rowlands; Nicholas S Peters; Alexander R Lyon; Sian E Harding; Kenneth T MacLeod Journal: Cardiovasc Res Date: 2017-12-01 Impact factor: 10.787